
Ortoma - Creating a good foundation for growth

Redeye makes minor revisions based on the Q2 report. We have changed the timing of some milestones to 2025e, but expect that they will receive the full amount by mid-2025e. The progress is evident in our view, even if it is still early in the commercialization process, and the recently announced milestone coming in Q3 is a good sign of progress. The outlook is still very promising. We nudge our fair value range upwards while increasing our Base case to SEK19.5 (18.7) per share

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ortoma - Creating a good foundation for growth](#)